Efficacy and Safety of Combination Therapy with Low-dose Pravastatin and Fenofibrate for Combined Hyperlipidemia
- VernacularTitle:小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症临床疗效及安全性
- Author:
Xiaohong SUN
;
Xiaoling PENG
;
Lei ZHU
- Publication Type:Journal Article
- Keywords:
Combined hyperlipidemia;
Pravastatin;
Fenofibrate;
Combination therapy
- From:
Chinese Journal of Hypertension
2007;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of this study was to evaluate the efficacy and safety of combination therapy with low-dose pravastatin and fenofibrate in patients with combined hyperlipidemia. Methods One hundred eighty nine patients with combined hyperlipidemia were randomly assigned to receive 10 mg pravastatin (n=64) or 200 mg fenofibrate (n=63), or a combination of 10 mg pravastatin and 200 mg fenofibrate (n=62) for 12 weeks. The patients in the monotherapy groups (n=35) whose lipid levels were not controlled after 12 weeks were randomly assigned to receive 20 mg pravastatin, or 200 mg fenofibrate, or a combination of 10 mg pravastatin and 200 mg fenofibrate for another 12 weeks. Lipid levels and adverse effects were assessed. Results After 12 weeks treatments, serum TC, LDL-C and TG levels were reduced and HDL-C was increased more significantly in combination therapy group, compared with 2 monotherapy groups (all P
